Prepared Remarks:

Operator

Welcome to the BioNTech first quarter 2022 update call. I would like to hand the call over to the vice president of investor relations and strategy, Sylke Maas. Please go ahead, Sylke.

Sylke Maas -- VP Investor Relations

Good morning, and good afternoon, and thank you for joining us today to review BioNTech's first quarter 2022 clinical and operational progress and financial results. A few housekeeping items before we start. Please use the slides that accompany the webcast and the first quarter 2022 press release. Both were issued this morning and can be found in the investor section of our website.

As outlined on Slide 2, today's presentation, we'll be making several forward-looking statements. These forward-looking statements include, but are not limited to, our current COVID-19 vaccine revenues, as they include figures that are derived from preliminary estimates provided by our partners; our estimated financial results for 2022; the continued global demand for our COVID-19 vaccine; our target vaccine production capacity for 2022 and beyond; our ability to supply our COVID-19 vaccine; the planned next steps in our pipeline programs; the timing for enrollment, initiation, completion, and reporting of data from our preclinical studies and our clinical trials; the timing of and our ability to obtain and maintain regulatory approval for our product candidates; and other risks described in our filings made with the U.S. Securities and Exchange Commission, including our most recent annual report on Form 20-F. As actual results could differ from those we currently anticipate, you are therefore cautioned not to place undue reliance on any forward-looking statements which speak only as of today, shared today during this conference call and webcast.

Also, please note that Slides 3 and 4 provide detailed and important safety information regarding our COVID-19 vaccine. Finally, you can see the agenda for today's call on Slide 5. It's my pleasure to introduce the members of BioNTech's management team participating in today's call. I'm joined today by our CEO and co-founder, Uğur Şahin; Ozlem Tureci, our chief medical officer and co-founder; Jens Holstein, our chief financial officer; and Ryan Richardson, our chief strategy officer.

I would like to turn the call over to Uğur Şahin.